Overview

A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

Status:
Terminated

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1b/2 multi-center, open-label study to establish the initial safety and to determine a recommended Phase 2 dose of B-701 in combination with pembrolizumab, and to determine safety, tolerability and efficacy of B-701 (vofatamab) plus pembrolizumab in the treatment of subjects with locally advanced or metastatic UCC, who have progressed following platinum-based chemotherapy and who have not received prior immune checkpoint inhibitor therapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

BioClin Therapeutics, Inc.
Rainier Therapeutics

Treatments:

Antibodies
Antibodies, Monoclonal
Pembrolizumab